Vital MABF - Search Results

1

Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.

Vecchia DD, Kanazawa LKS, Wendler E, de Almeida Soares Hocayen P, Bruginski E, Campos FR, Stern CAJ, Vital MABF, Miyoshi E, Wöhr M, Schwarting RKW, Andreatini R. Vecchia DD, et al. Among authors: vital mabf. Behav Brain Res. 2018 Apr 16;342:1-10. doi: 10.1016/j.bbr.2017.12.041. Epub 2018 Jan 4. Behav Brain Res. 2018. PMID: 29307665

2

The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission.

Joca SR, Skalisz LL, Beijamini V, Vital MA, Andreatini R. Joca SR, et al. Eur Neuropsychopharmacol. 2000 Jul;10(4):223-8. doi: 10.1016/s0924-977x(00)00079-1. Eur Neuropsychopharmacol. 2000. PMID: 10871703

3

Phosphatidylserine reverses reserpine-induced amnesia.

Alves CS, Andreatini R, da Cunha C, Tufik S, Vital MA. Alves CS, et al. Eur J Pharmacol. 2000 Sep 15;404(1-2):161-7. doi: 10.1016/s0014-2999(00)00607-5. Eur J Pharmacol. 2000. PMID: 10980275

4

Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia.

Da Cunha C, Gevaerd MS, Vital MA, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS. Da Cunha C, et al. Behav Brain Res. 2001 Sep 28;124(1):9-18. doi: 10.1016/s0166-4328(01)00211-x. Behav Brain Res. 2001. PMID: 11423161

5

Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.

Reksidler AB, Lima MM, Dombrowski P, Andersen ML, Zanata SM, Andreatini R, Tufik S, Vital MA. Reksidler AB, et al. J Neurosci Methods. 2008 Jan 30;167(2):268-77. doi: 10.1016/j.jneumeth.2007.08.024. Epub 2007 Sep 5. J Neurosci Methods. 2008. PMID: 17931705

6

Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission.

Da Cunha C, Wietzikoski EC, Ferro MM, Martinez GR, Vital MA, Hipólide D, Tufik S, Canteras NS. Da Cunha C, et al. Behav Brain Res. 2008 Jun 3;189(2):364-72. doi: 10.1016/j.bbr.2008.01.012. Epub 2008 Feb 5. Behav Brain Res. 2008. PMID: 18328580

7

Non-motor function of the midbrain dopaminergic neurons.

Da Cunha C, Wietzikoski EC, Bortolanza M, Dombrowski PA, dos Santos LM, Boschen SL, Miyoshi E, Vital MA, Boerngen-Lacerda R, Andreatini R. Da Cunha C, et al. J Neural Transm Suppl. 2009;(73):147-60. J Neural Transm Suppl. 2009. PMID: 20411775 Review.

8

Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.

Bonato JM, Bassani TB, Milani H, Vital MABF, de Oliveira RMW. Bonato JM, et al. Among authors: vital mabf. Exp Neurol. 2018 Feb;300:188-200. doi: 10.1016/j.expneurol.2017.11.009. Epub 2017 Nov 21. Exp Neurol. 2018. PMID: 29162435

9

Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials.

Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R. Raupp-Barcaro IF, et al. Braz J Psychiatry. 2018 Oct-Dec;40(4):449-458. doi: 10.1590/1516-4446-2017-2393. Epub 2018 Jun 11. Braz J Psychiatry. 2018. PMID: 29898194 Free PMC article. Review.

10

PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.

Machado MMF, Bassani TB, Cóppola-Segovia V, Moura ELR, Zanata SM, Andreatini R, Vital MABF. Machado MMF, et al. Among authors: vital mabf. Pharmacol Rep. 2019 Aug;71(4):556-564. doi: 10.1016/j.pharep.2018.11.005. Epub 2018 Nov 30. Pharmacol Rep. 2019. PMID: 31132685

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page